Weekly Spotlight - 12.12.24

Latest News

Huntington Disease Study Finds No Evidence of Chemical Pathway Issues

A study on Huntington's disease found that a specific chemical pathway in the body, called the kynurenine pathway, doesn’t seem to work differently in people with the disease compared to healthy individuals. Tests on blood and spinal fluid showed no noticeable differences, meaning these chemicals likely won’t be helpful in tracking the disease or its treatment.

Promising Advances in Targeting AGEs for Neurodegenerative Disease Treatment

AGEs are linked to neurodegenerative diseases like, Parkinson, and Huntington. They worsen these conditions by promoting harmful protein interactions and triggering damaging processes. Efforts to reduce AGEs or block their effects offer hope in slowing disease progression, though effective treatments remain challenging.

Exploring Visual Attention Deficits in Neurodegenerative Diseases: A Hopeful Perspective

The study highlights that neurodegenerative diseases like Huntington and show both spatial and non-spatial attention deficits, similar to neglect. Using Bundesen theory, researchers found slowed processing and spatial biases. This understanding could enhance future research, offering hope for better insights into these conditions.

uniQure AMT-130: A Hopeful Leap for Huntington Treatment Approval

uniQure AMT-130 gene therapy for Huntington disease is progressing towards accelerated FDA approval. The therapy, requiring only one lifetime dose, shows promise in improving symptoms. Key metrics, cUHDRS and NfL, are now accepted by the FDA, paving the way for future treatments. 2025 will be pivotal.